Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
---|
C009505 |
4,4'-diaminodiphenylmethane |
4,4'-diaminodiphenylmethane results in increased expression of SSPN mRNA | increases expression | 18648102
|
D019256 |
Cadmium Chloride |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromium oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of SSPN mRNA | affects cotreatment|decreases expression | 12634122
|
C023600 |
chromium oxide |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromium oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of SSPN mRNA | affects cotreatment|decreases expression | 12634122
|
C017133 |
chromous chloride |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromium oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of SSPN mRNA | affects cotreatment|decreases expression | 12634122
|
D006830 |
Hydralazine |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SSPN mRNA | affects cotreatment|increases expression | 17183730
|
C008261 |
lead acetate |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromium oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of SSPN mRNA | affects cotreatment|decreases expression | 12634122
|
C017947 |
sodium arsenite |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromium oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of SSPN mRNA | affects cotreatment|decreases expression | 12634122
|
D018038 |
Sodium Selenite |
Sodium Selenite results in decreased expression of SSPN mRNA | decreases expression | 18175754
|
C004648 |
testosterone enanthate |
testosterone enanthate affects the expression of SSPN mRNA | affects expression | 17440010
|
D014635 |
Valproic Acid |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SSPN mRNA | affects cotreatment|increases expression | 17183730
|
C025643 |
vinclozolin |
vinclozolin affects the expression of SSPN mRNA | affects expression | 19015723
|
Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
---|
MESH:D000014 |
Abnormalities, Drug-Induced |
|
Valproic Acid |
3.68 | 8875741 |
MESH:D000015 |
Abnormalities, Multiple |
|
Valproic Acid |
4.07 | 19490988 |
MESH:D000236 |
Adenoma |
|
4,4'-diaminodiphenylmethane |
2.83 | 3712494 |
MESH:D000310 |
Adrenal Gland Neoplasms |
|
sodium arsenite |
4.92 | 15276417 |
MESH:D018246 |
Adrenocortical Adenoma |
|
sodium arsenite |
5.12 | 16712894 17306315 |
MESH:D000550 |
Amblyopia |
|
Valproic Acid |
5.45 | 17688650 |
MESH:D001008 |
Anxiety Disorders |
|
Valproic Acid |
9.23 | 17497229 |
MESH:D001008 |
Anxiety Disorders |
|
vinclozolin |
9.23 | 19015723 |
MESH:D001321 |
Autistic Disorder |
|
Valproic Acid |
1.99 | 18775368 17688650 18316065 17157402 18985861 19232924 18177632 17507914 18558336 19460635 18396377 16609825 15238991 20603192 18940202 |
MESH:D001660 |
Biliary Tract Diseases |
|
4,4'-diaminodiphenylmethane |
5.24 | 11289319 1440618 |
MESH:D001714 |
Bipolar Disorder |
|
Valproic Acid |
3.14 | 20046352 17594078 |
MESH:D001848 |
Bone Diseases, Developmental |
|
Valproic Acid |
3.49 | 8888407 |
MESH:D006528 |
Carcinoma, Hepatocellular |
|
4,4'-diaminodiphenylmethane |
3.09 | 3581430 7296757 |
MESH:D006528 |
Carcinoma, Hepatocellular |
|
sodium arsenite |
3.09 | 16507464 15276417 17306315 |
MESH:D002292 |
Carcinoma, Renal Cell |
|
4,4'-diaminodiphenylmethane |
2.73 | 7296757 |
MESH:D002294 |
Carcinoma, Squamous Cell |
|
sodium arsenite |
2.41 | 18572023 |
MESH:D002471 |
Cell Transformation, Neoplastic |
|
4,4'-diaminodiphenylmethane |
7.05 | 7505956 |
MESH:D002471 |
Cell Transformation, Neoplastic |
|
sodium arsenite |
7.05 | 19524636 20056578 |
MESH:D002659 |
Child Development Disorders, Pervasive |
|
Valproic Acid |
2.75 | 20734317 |
MESH:D002779 |
Cholestasis |
|
4,4'-diaminodiphenylmethane |
3.25 | 19486331 9022650 |
MESH:D019457 |
Chromosome Breakage |
|
Sodium Selenite |
4.93 | 15894690 |
MESH:D019465 |
Craniofacial Abnormalities |
|
lead acetate |
3.20 | 19769572 |
MESH:D019465 |
Craniofacial Abnormalities |
|
Valproic Acid |
3.20 | 17688650 8888407 16575769 |
MESH:D003456 |
Cryptorchidism |
|
vinclozolin |
4.50 | 14966744 |
MESH:D017449 |
Dermatitis, Allergic Contact |
|
4,4'-diaminodiphenylmethane |
2.97 | 2524372 18759878 8156756 11298694 11906362 8970840 14531868 12868966 |
MESH:D003877 |
Dermatitis, Contact |
|
4,4'-diaminodiphenylmethane |
3.64 | 2952479 3621924 |
MESH:D003920 |
Diabetes Mellitus |
|
Sodium Selenite |
3.90 | 16285004 |
MESH:D056486 |
Drug-Induced Liver Injury |
|
4,4'-diaminodiphenylmethane |
6.51 | 6679447 8291058 1440618 18692083 16192314 18289764 9328219 9653073 11289319 18648102 6482804 9022650 7440962 |
MESH:D056486 |
Drug-Induced Liver Injury |
|
Sodium Selenite |
6.51 | 15131321 |
MESH:D056486 |
Drug-Induced Liver Injury |
|
Valproic Acid |
6.51 | 19641884 1733752 |
MESH:D004421 |
Dystonia |
|
Valproic Acid |
4.20 | 1851702 |
MESH:D004831 |
Epilepsies, Myoclonic |
|
Valproic Acid |
4.33 | 3659116 17275665 |
MESH:D004828 |
Epilepsies, Partial |
|
Valproic Acid |
4.13 | 16628512 3922381 |
MESH:D004827 |
Epilepsy |
|
Valproic Acid |
3.00 | 18234410 20417680 |
MESH:D004832 |
Epilepsy, Absence |
|
Valproic Acid |
3.71 | 6426943 7562514 6254150 |
MESH:D017029 |
Epilepsy, Complex Partial |
|
Valproic Acid |
4.47 | 7750514 |
MESH:D004830 |
Epilepsy, Tonic-Clonic |
|
Valproic Acid |
4.26 | 3659116 |
MESH:D004938 |
Esophageal Neoplasms |
|
4,4'-diaminodiphenylmethane |
2.14 | 3581430 |
MESH:D005234 |
Fatty Liver |
|
Valproic Acid |
3.44 | 19224547 14986274 |
MESH:D005315 |
Fetal Diseases |
|
Valproic Acid |
5.10 | 16575769 |
MESH:D005317 |
Fetal Growth Retardation |
|
lead acetate |
11.74 | 19769572 |
MESH:D005317 |
Fetal Growth Retardation |
|
Valproic Acid |
11.74 | 18558336 8888407 |
MESH:D005350 |
Fibroma |
|
4,4'-diaminodiphenylmethane |
5.24 | 6705139 |
MESH:D030342 |
Genetic Diseases, Inborn |
|
vinclozolin |
5.13 | 16973722 |
MESH:D005832 |
Genital Diseases, Male |
|
vinclozolin |
5.52 | 16417039 |
MESH:D005833 |
Genital Neoplasms, Female |
|
sodium arsenite |
4.87 | 16452187 |
MESH:D006042 |
Goiter |
|
4,4'-diaminodiphenylmethane |
4.19 | 7505956 |
MESH:D006505 |
Hepatitis |
|
4,4'-diaminodiphenylmethane |
3.67 | 6705139 |
MESH:D019247 |
HIV Wasting Syndrome |
|
testosterone enanthate |
5.96 | 17440010 |
MESH:D006689 |
Hodgkin Disease |
|
sodium arsenite |
3.27 | 12676792 |
MESH:D006849 |
Hydrocephalus |
|
Valproic Acid |
5.06 | 17688650 |
MESH:D006965 |
Hyperplasia |
|
4,4'-diaminodiphenylmethane |
4.11 | 15034207 |
MESH:D046110 |
Hypertension, Pregnancy-Induced |
|
Hydralazine |
4.80 | 16612254 |
MESH:D007248 |
Infertility, Male |
|
sodium arsenite |
7.15 | 15346721 12646999 |
MESH:D007248 |
Infertility, Male |
|
vinclozolin |
7.15 | 16467254 |
MESH:D007333 |
Insulin Resistance |
|
Sodium Selenite |
3.36 | 14714311 |
MESH:D007565 |
Jaundice |
|
4,4'-diaminodiphenylmethane |
5.24 | 8074119 9022650 |
MESH:D007674 |
Kidney Diseases |
|
Cadmium Chloride |
6.68 | 16962696 |
MESH:D007674 |
Kidney Diseases |
|
sodium arsenite |
6.68 | 20008137 |
MESH:D007680 |
Kidney Neoplasms |
|
4,4'-diaminodiphenylmethane |
3.08 | 6582329 |
MESH:D015470 |
Leukemia, Myeloid, Acute |
|
Valproic Acid |
2.17 | 17596541 16294345 |
MESH:D007984 |
Leydig Cell Tumor |
|
vinclozolin |
4.93 | 16417039 |
MESH:D008105 |
Liver Cirrhosis, Biliary |
|
4,4'-diaminodiphenylmethane |
3.28 | 9327722 15034207 |
MESH:D008113 |
Liver Neoplasms |
|
sodium arsenite |
2.41 | 16712894 15276417 |
MESH:D008114 |
Liver Neoplasms, Experimental |
|
4,4'-diaminodiphenylmethane |
2.61 | 3712494 1399818 6587162 598648 |
MESH:D008171 |
Lung Diseases |
|
sodium arsenite |
3.26 | 19095001 |
MESH:D017563 |
Lung Diseases, Interstitial |
|
Valproic Acid |
4.48 | 17228818 |
MESH:D008175 |
Lung Neoplasms |
|
sodium arsenite |
1.89 | 19931552 17306315 17077188 15276417 16712894 |
MESH:D016393 |
Lymphoma, B-Cell |
|
Sodium Selenite |
4.21 | 14737004 |
MESH:D008545 |
Melanoma |
|
sodium arsenite |
2.05 | 19082730 16487513 |
MESH:D008881 |
Migraine Disorders |
|
Valproic Acid |
3.29 | 18803445 18765137 |
MESH:D009139 |
Musculoskeletal Abnormalities |
|
Valproic Acid |
4.17 | 8888407 |
MESH:D009190 |
Myelodysplastic Syndromes |
|
Valproic Acid |
3.23 | 17596541 |
MESH:D009362 |
Neoplasm Metastasis |
|
4,4'-diaminodiphenylmethane |
2.52 | 3581430 |
MESH:D009369 |
Neoplasms |
|
sodium arsenite |
2.56 | 11559025 |
MESH:D009374 |
Neoplasms, Experimental |
|
sodium arsenite |
3.84 | 20056578 |
MESH:D009436 |
Neural Tube Defects |
|
4,4'-diaminodiphenylmethane |
12.66 | 6679447 |
MESH:D009436 |
Neural Tube Defects |
|
sodium arsenite |
12.66 | 12854658 |
MESH:D009436 |
Neural Tube Defects |
|
Valproic Acid |
12.66 | 16359493 8888407 |
MESH:D009784 |
Occupational Diseases |
|
4,4'-diaminodiphenylmethane |
3.55 | 4026338 6482804 |
MESH:D009902 |
Optic Neuritis |
|
4,4'-diaminodiphenylmethane |
5.24 | 3988306 |
MESH:D010051 |
Ovarian Neoplasms |
|
sodium arsenite |
2.47 | 17306315 15276417 |
MESH:D010212 |
Papilloma |
|
4,4'-diaminodiphenylmethane |
3.66 | 7296757 |
MESH:D010787 |
Photosensitivity Disorders |
|
4,4'-diaminodiphenylmethane |
4.69 | 6228378 |
MESH:D011297 |
Prenatal Exposure Delayed Effects |
|
Valproic Acid |
10.38 | 20603192 |
MESH:D011297 |
Prenatal Exposure Delayed Effects |
|
vinclozolin |
10.38 | 18220299 18042343 19015723 |
MESH:D011469 |
Prostatic Diseases |
|
vinclozolin |
5.13 | 18220299 |
MESH:D011471 |
Prostatic Neoplasms |
|
sodium arsenite |
3.31 | 16039940 |
MESH:D011471 |
Prostatic Neoplasms |
|
Sodium Selenite |
3.31 | 18760546 |
MESH:D011472 |
Prostatitis |
|
vinclozolin |
5.13 | 18629315 |
MESH:D019310 |
Pseudolymphoma |
|
Valproic Acid |
4.76 | 11422049 12752131 |
MESH:D012162 |
Retinal Degeneration |
|
4,4'-diaminodiphenylmethane |
3.48 | 3692021 |
MESH:D012208 |
Rhabdomyosarcoma |
|
Valproic Acid |
4.32 | 19155313 |
MESH:D012559 |
Schizophrenia |
|
Valproic Acid |
2.08 | 19110320 15737665 |
MESH:D012640 |
Seizures |
|
Valproic Acid |
2.83 | 15475178 14763951 1511512 17978042 16876388 3137016 11738929 11044598 |
MESH:D012878 |
Skin Neoplasms |
|
sodium arsenite |
2.75 | 19524636 18572023 |
MESH:D016135 |
Spinal Dysraphism |
|
sodium arsenite |
9.91 | 12854658 |
MESH:D016135 |
Spinal Dysraphism |
|
Valproic Acid |
9.91 | 19490988 |
MESH:D013226 |
Status Epilepticus |
|
Valproic Acid |
4.76 | 12833885 |
MESH:D013964 |
Thyroid Neoplasms |
|
4,4'-diaminodiphenylmethane |
2.99 | 7505956 6582329 3712494 6587162 1399818 |
MESH:D014178 |
Translocation, Genetic |
|
Valproic Acid |
5.45 | 17262798 |
MESH:D020194 |
Unverricht-Lundborg Syndrome |
|
Valproic Acid |
4.71 | 3119515 |
MESH:D001749 |
Urinary Bladder Neoplasms |
|
4,4'-diaminodiphenylmethane |
5.25 | 8074119 |
MESH:D001749 |
Urinary Bladder Neoplasms |
|
sodium arsenite |
5.25 | 16452187 11723127 16712894 17306315 |
MESH:D014564 |
Urogenital Abnormalities |
|
Valproic Acid |
4.82 | 8888407 |
MESH:D002583 |
Uterine Cervical Neoplasms |
|
sodium arsenite |
3.90 | 11813266 |
MESH:D014652 |
Vascular Diseases |
|
sodium arsenite |
4.62 | 17056641 |